Nanobiotix (France) Today
| NANO Stock | EUR 3.63 0.16 4.61% |
PerformanceInsignificant
| Odds Of DistressBelow Average
|
Nanobiotix is trading at 3.63 as of the 19th of March 2025, a 4.61% up since the beginning of the trading day. The stock's open price was 3.47. Nanobiotix has about a 32 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 19th of March 2025. Click here to learn more.
Nanobiotix SA, a late stage clinical company, develops and sells nanomedicine for the treatment of cancer worldwide. Nanobiotix SA was incorporated in 2003 and is headquartered in Paris, France. NANOBIOTIX operates under Drug Manufacturers - Major classification in France and is traded on Paris Stock Exchange. The company has 34.88 M outstanding shares. More on Nanobiotix SA
Moving against Nanobiotix Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Nanobiotix Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Nanobiotix's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Nanobiotix or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Drug Manufacturers - Major, Healthcare (View all Sectors) |
Nanobiotix SA (NANO) is traded on Euronext Paris in France and employs 103 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 115.07 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Nanobiotix's market, we take the total number of its shares issued and multiply it by Nanobiotix's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Nanobiotix SA operates under Healthcare sector and is part of Drug Manufacturers - Major industry. The entity has 34.88 M outstanding shares.
Nanobiotix SA has accumulated about 36.2 M in cash with (29.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.85.
Check Nanobiotix Probability Of Bankruptcy
Ownership AllocationNanobiotix SA maintains a total of 34.88 Million outstanding shares. Nanobiotix SA secures 3.78 % of its outstanding shares held by insiders and 25.56 % owned by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Nanobiotix Ownership Details
Nanobiotix SA Risk Profiles
Although Nanobiotix's alpha and beta are two of the key measurements used to evaluate Nanobiotix's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.63 | |||
| Semi Deviation | 2.8 | |||
| Standard Deviation | 3.97 | |||
| Variance | 15.76 |
Nanobiotix Stock Against Markets
| NANO | 4.61 |
| Competition | Refresh |
Be your own money manager
Our tools can tell you how much better you can do entering a position in Nanobiotix without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Bond Analysis Now
Bond AnalysisEvaluate and analyze corporate bonds as a potential investment for your portfolios. |
| All Next | Launch Module |
Nanobiotix Corporate Management
Elected by the shareholders, the Nanobiotix's board of directors comprises two types of representatives: Nanobiotix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nanobiotix. The board's role is to monitor Nanobiotix's management team and ensure that shareholders' interests are well served. Nanobiotix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nanobiotix's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sarah Gaubert | Head Department | Profile | |
| Elsa Borghi | Head Discovery | Profile | |
| Brandon Owens | VP Communication | Profile | |
| Earl Bergey | CoFounder | Profile | |
| Kathryn McNeil | VP Relations | Profile | |
| AnneJuliette MA | Chief Board | Profile | |
| Bart Rhijn | CFO Board | Profile |
Other Information on Investing in Nanobiotix Stock
Nanobiotix financial ratios help investors to determine whether Nanobiotix Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nanobiotix with respect to the benefits of owning Nanobiotix security.